Skip to main content

Table 1 The association between DPYSL2 expression and prognosis in LUAD based on Kaplan–Meier plotter analysis

From: DPYSL2 as potential diagnostic and prognostic biomarker linked to immune infiltration in lung adenocarcinoma

  Overall survival (n = 719)   Progression-free survival (n = 641)
N HR (95% CI) p value   N HR (95% CI) p value
Gender        
 Female 317 0.29 (0.19–0.45) 2.3e−09   235 1.99 (1.25–3.17) 0.0032
 Male 344 0.49 (0.34–0.68) 2.6e−05   226 2.96 (1.86–4.7) 1.5e−06
Stage        
 1 370 0.34 (0.22–0.52) 2.1e−07   283 2.75 (1.65–4.61) 5.8e−05
 2 136 0.43 (0.26–0.72) 8e−04   103 1.38 (0.8–2.4) 0.25
 3 24 0.72 (0.25–2.07) 0.54   10
 4 4   0
T stage        
 1 123 0.67 (0.36–1.24) 0.2   47 7.47 (0.89–62.42) 0.029
 2 105 0.77 (0.44–1.33) 0.34   93 1.59 (0.84–3.01) 0.15
 3 4   2
 4 0   0
N stage        
 0 184 1.87 (1.14–3.05) 0.011   102 1.49 (0.68–3.25) 0.31
 1 44 1.18 (0.54–2.57) 0.68   38 3.16 (1.23–8.13) 0.012
 2 3   2
M stage        
 0 231 1.56 (1.04–2.34) 0.028   142 2.17 (1.19–3.93) 0.0093
 1 1   0
Smoke        
 Ever 246 2.03 (1.25–3.28) 0.0033   243 2.29(1.46–3.6) 0.00021
 Never 143 3.42 (1.35–8.62) 0.0057   143 3.1 (1.58–6.07) 5e−04
  1. HR hazard ratio, CI confidence interval. Values in bold indicate p < 0.05